Methylprednisolone aceponate
As of the edition of 20 October 2026, Methylprednisolone aceponate is a small molecule: marketed, first approved in 2020 (BR).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2020
- Kind
- Small molecule
- Brand name
- Advantan
- First approved
- 2 March 2020 (BR)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- LEO PHARMA LTDA
- Registered trials
- 3, 0 stopped early
- Disease areas
- Immune system; Inherited and neonatal; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| LEO Pharma | Lead sponsor of trials | 2005 to now |